Aderemi Adewale Victor, Ayeleso Ademola Olabode, Oyedapo Oluboade Oluokun, Mukwevho Emmanuel
Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, UK.
Department of Medical Biochemistry, Osun State University, Osogbo PMB 4494, Nigeria.
Metabolites. 2021 Jun 25;11(7):418. doi: 10.3390/metabo11070418.
Metabolomics is a branch of 'omics' sciences that utilises a couple of analytical tools for the identification of small molecules (metabolites) in a given sample. The overarching goal of metabolomics is to assess these metabolites quantitatively and qualitatively for their diagnostic, therapeutic, and prognostic potentials. Its use in various aspects of life has been documented. We have also published, howbeit in animal models, a few papers where metabolomic approaches were used in the study of metabolic disorders, such as metabolic syndrome, diabetes, and obesity. As the goal of every research is to benefit humankind, the purpose of this review is to provide insights into the applicability of metabolomics in medicine vis-à-vis its role in biomarker discovery for disease diagnosis and management. Here, important biomarkers with proven diagnostic and therapeutic relevance in the management of disease conditions, such as Alzheimer's disease, dementia, Parkinson's disease, inborn errors of metabolism (IEM), diabetic retinopathy, and cardiovascular disease, are noted. The paper also discusses a few reasons why most metabolomics-based laboratory discoveries are not readily translated to the clinic and how these could be addressed going forward.
代谢组学是“组学”科学的一个分支,它利用一些分析工具来鉴定给定样本中的小分子(代谢物)。代谢组学的总体目标是对这些代谢物的诊断、治疗和预后潜力进行定量和定性评估。其在生活各个方面的应用已有文献记载。我们也发表过一些论文,尽管是在动物模型中,其中使用代谢组学方法研究了代谢紊乱,如代谢综合征、糖尿病和肥胖症。由于每项研究的目标都是造福人类,本综述的目的是深入探讨代谢组学在医学中的适用性及其在疾病诊断和管理的生物标志物发现中的作用。在此,记录了在疾病管理中具有已证实的诊断和治疗相关性的重要生物标志物,如阿尔茨海默病、痴呆症、帕金森病、先天性代谢缺陷(IEM)、糖尿病视网膜病变和心血管疾病。本文还讨论了为什么大多数基于代谢组学的实验室发现不能轻易转化为临床应用,以及未来如何解决这些问题。